Home > Healthcare > Pharmaceuticals > Finished Drug Form > Anti-Obesity Drugs Market

Anti-Obesity Drugs Market Trends

Report ID: GMI10074
Published Date: Jul 2024
Report Format: PDF

Download Free Sample

Anti-Obesity Drugs Market Trends

There's a growing emphasis on personalized approaches to obesity treatment, considering individual differences in genetics, metabolism, and lifestyle factors. Advances in biomarker research and genetic testing are facilitating the development of tailored treatment regimens, including pharmacotherapy, to optimize outcomes for patients.
Combination therapies involving multiple mechanisms of action are gaining traction in the treatment of obesity. By targeting different pathways involved in appetite regulation, metabolism, or fat absorption, these therapies aim to enhance efficacy while minimizing side effects. Examples include fixed-dose combinations of drugs targeting the central nervous system and peripherally acting agents.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Anti-obesity drugs industry was valued at USD 5.6 billion in 2023 and will exhibit 27% CAGR from 2024 to 2032, attributed to the rising prevalence of obesity worldwide, increasing awareness of the health risks associated with obesity, and advancements in drug development.

Anti-obesity drugs industry from the prescription drugs segment recorded USD 4.1 billion in 2023, owing to the effectiveness and reliability of prescription medications in managing obesity.

North America anti-obesity drugs industry size will reach USD 21.9 billion by 2032, driven by the high prevalence of obesity, robust healthcare infrastructure, and significant investments in R&D.

Prominent players operating in anti-obesity drugs industry are Arena Pharmaceuticals, Inc., AstraZeneca PLC, Boehringer Ingelheim International GmbH, Currax Pharmaceuticals LLC, Eli Lily & Co, F. Hoffmann-La Roche Ltd., Gelesis, GlaxoSmithKline plc, Merck & Co., Inc., Novartis AG, and Novo Nordisk A/S, among others.